Emerging blood-based biomarkers for Alzheimer disease

Cleve Clin J Med. 2020 Aug 31;87(9):537-539. doi: 10.3949/ccjm.87a.20133.

Authors

Lynn M Bekris¹, James B Leverenz²

Affiliations

¹ Associate Staff, Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic; Assistant Professor of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH bekrisl@ccf.org.
² Director, Cleveland Lou Ruvo Center for Brain Health, Neurological Institute, and Joseph Hahn, MD, Endowed Chair of the Cleveland Clinic Neurological Institute, Cleveland Clinic.

PMID: 32868302
DOI: 10.3949/ccjm.87a.20133

No abstract available

MeSH terms

Aged
Aged, 80 and over
Alzheimer Disease / diagnosis*
Amyloid beta-Peptides / blood*
Biomarkers / blood
Female
Humans
Male
Phosphorylation
tau Proteins / blood*

Substances

Amyloid beta-Peptides
Biomarkers
MAPT protein, human
tau Proteins

Grants and funding

P30 AG062428/AG/NIA NIH HHS/United States